SK pharmteco Achieves Highest-Level My Green Lab Certifications Across Europe and Asia
SK pharmteco, a global contract development and manufacturing organization (CDMO), today announced a significant milestone in its commitment to environmental sustainability by earning four My Green Lab certifications, including two at the program’s highest level, Green. The remaining two labs earned Gold certification, reflecting advanced sustainability performance and progression toward full Green maturity.
The certified facilities are Small Molecule Europe (Swords, Ireland) and Small Molecule Asia (Daejeon, South Korea), and the certifications cover the areas of Quality Control, Process Research & Development, and Analytical Research & Development.
My Green Lab certification is widely regarded as the global standard for laboratory sustainability, recognized by the United Nations Race to Zero campaign for its rigor in advancing credible decarbonization. Green certification is the program’s highest designation, reserved for laboratories that demonstrate exceptional, independently verified performance in reducing environmental impact while maintaining scientific excellence. Gold certification represents advanced performance and a clear progression toward Green.
SK pharmteco began its journey to achieve My Green Lab certifications in the fall of 2024, with a long-term goal of reaching the highest certification level by 2030.
“Achieving Green and Gold certifications across multiple regions in parallel is not just a compliance milestone; it signals where scientific operations must go next,” said Darryl Ratty, Executive Director, Global ESG of SK pharmteco. “Sustainability in R&D and quality labs is no longer a side project; it’s a performance expectation. We’re embedding it into how science is planned, executed, and validated across our global laboratory network.”
SK pharmteco's pursuit of My Green Lab Certification directly supports its three-pronged sustainability strategy: Responsible Manufacturing through optimized lab practices, Decarbonizing Operations with enhanced energy efficiency, and Championing Waste-Less Innovation via robust waste reduction initiatives. Additionally, it demonstrates the company’s ongoing commitment to integrating sustainable practices into every facet of its operations, contributing to a greener future for the industry.
About SK pharmteco
SK pharmteco is a global contract development and manufacturing organization (CDMO) with production sites, research & development facilities, and analytical laboratories across the U.S., Europe, and South Korea. The company partners with biopharmaceutical companies of all sizes to manufacture Active Pharmaceutical Ingredients (API) and intermediates, cell and gene therapy technologies, registered starting materials, and analytical services for the biopharmaceutical industry worldwide. SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic investment company for SK Group, South Korea’s second-largest conglomerate.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251028846076/en/
Contacts
Keith Bowermaster, APR, CCMP
Communications Consultant
keith.bowermaster@skpt.com
Website:www.skpharmteco.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.skpharmteco
.com&esheet=54346004&newsitemid=20251028846076&lan=en-US&anchor=www.skpharmteco.
com&index=1&md5=0c41fd7ce70ea17b8704310a8a27bd51
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines to Present at Upcoming Investor Conferences28.10.2025 12:01:00 EET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in fireside chats at two upcoming investor conferences: Guggenheim Second Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 9:30 am EST; and Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 4:00 pm GMT/11:00 am EST Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through
Allianz Reports Safety Gains From Automated Mobility and Urges EU-Wide “Driving License” for Autonomous Vehicles28.10.2025 11:05:00 EET | Press release
The promise of autonomous mobility is not just a technological leap – it represents a transformation in safety, comfort, and accessibility that is already underway with Level 3 vehicles on European roads and Level 4 systems operating in real-world test fields. At the 13th Allianz Motor Day in 2025, hosted by the Allianz Center for Technology (AZT), Allianz unveiled significant safety gains from autonomous vehicles and calls for EU-wide testing standards to ensure their safe integration into European roads, including questions about vehicle safety, liability, the use of in-vehicle data from autonomous vehicles (AVs), and more inclusive mobility. The company already insures test fields in several countries, including Germany, Norway, and Singapore. AZT research and proprietary claims analysis indicate a significant decline in motor liability claims frequency driven by advanced driver assistance systems (ADAS) now available in select models. While these systems already demonstrate impress
Ares Management and Slate Asset Management to Acquire Polish Real Estate Portfolio Valued at Over €300 Million From Trei Real Estate28.10.2025 10:15:00 EET | Press release
Ares Management Corporation (“Ares”) (NYSE: ARES), a leading global alternative investment manager, and Slate Asset Management (“Slate”), a global investor and manager focused on essential real estate and infrastructure, today announced that a joint venture between Ares Real Estate funds (“Ares Real Estate”) and Slate has agreed to acquire a portfolio of 36 properties in Poland (the “Portfolio”) from Trei Real Estate, an internationally active developer and asset manager. The Portfolio is valued at over €300 million. The Portfolio comprises 36 recently developed and fully occupied convenience-led retail parks strategically located across major Polish metropolitan areas near large catchment populations. The assets are inflation-protected through CPI-linked lease agreements underpinned by tenants with strong covenants. Most of the Portfolio’s income is derived from large regional retailers and essential goods providers, including grocers and pharmacies. “This transaction underlines our c
Kemwell Biopharma Facility in Bengaluru Successfully Completes U.S. FDA Inspection for Commercial Drug-Product Manufacturing28.10.2025 08:00:00 EET | Press release
Kemwell Biopharma Pvt Ltd (“Kemwell”), a leading global biologics Contract Development and Manufacturing Organization (CDMO), announced today that its drug-product manufacturing facility in Bengaluru has successfully completed a U.S. Food and Drug Administration (FDA) pre-approval inspection (PAI) and is now cleared for the commercial manufacturing and testing of injectable products destined for the U.S. market. This milestone marks the approval of the first product to get U.S. FDA clearance for commercial supply from Kemwell’s Bengaluru drug-product facility since the site became a dedicated biologics campus eight years ago. It demonstrates the company’s ability to meet stringent current Good Manufacturing Practice (cGMP) and aseptic drug-product manufacturing standards. “Achieving FDA clearance for commercial manufacturing from our Bengaluru site marks a defining moment in Kemwell’s growth journey,” said Anurag Bagaria, Chairman and CEO, Kemwell Biopharma. “It reflects our team’s ste
Uzbekistan's National Payment System HUMO and Ant International’s Alipay+ Partner to Facilitate Cross-Border QR Payments28.10.2025 07:55:00 EET | Press release
Alipay+, Ant International’s global wallet gateway, and HUMO, the national payment system in Uzbekistan, announced the partnership in Beijing to facilitate inbound and outbound cross-border QR payments. The Octomobile app by Octobank will be the first Uzbek e-wallet integrated with Alipay+, with more HUMO-connected local e-wallets and bank apps expected to join by the end of the year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027737149/en/ The delegation from HUMO and Octomobile experienced Alipay+ payments at Beijing's Wukesong Wanda Plaza HUMO has become the tenth national QR code network to partner with Alipay+. In the initial phase, HUMO users from Uzbekistan will be able to travel in China and over 50 other countries—including Kazakhstan, Thailand, UAE, United States and beyond—effortlessly for payments in Uzbek som through their preferred home payment methods / banking apps, across their travel experience, incl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom